Acadia Pharmaceuticals Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ACAD | AXSM | PRAX | MPLT | HRMY | BHVN | |
|---|---|---|---|---|---|---|
| Market cap | 3.34B | 8.70B | 7.02B | 477.95M | 2.23B | 1.78B |
| P/E (TTM) | 8.7 | — | — | — | 12.3 | — |
| Forward P/E | 21.5 | 35.6 | -26.9 | -2.5 | 5.5 | -6.3 |
| Price/book | 2.6 | 104.2 | 5.2 | 1.1 | 2.2 | 145.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −3.24% | +34.39% | +396.48% | −51.85% | +52.81% | −29.11% |
| Today | −1.87% | −1.40% | −3.26% | −2.60% | −5.09% | −2.24% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ACAD news ›Acadia Pharmaceuticals | Science & Technology
Cummings, J. et al. (2014) ‘Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial’, The Lancet, 383(9916), pp. 533–540. Glaze, D.G. et al. (2019) ‘A Double-Blind, Randomized,…
Bronstein, Gewirtz & Grossman, LLC Is Investigating ACADIA Pharmaceuticals Inc. (ACAD) And Encourages Investors to Connect
ACCESS Newswire Bronstein, Gewirtz & Grossman, LLC Is Investigating ACADIA Pharmaceuticals Inc. (ACAD) And Encourages Investors to Connect Sunday, 11 October 2026 01:00 PM What's Next for Acadia Investors? No Cost to Acadia Investors We,…
Analysts’ Top Healthcare Picks: Kyverna Therapeutics, Inc. (KYTX), ACADIA Pharmaceuticals (ACAD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kyverna Therapeutics, Inc. (KYTX), ACADIA Pharmaceuticals (ACAD) and Cullinan Management (CGEM) with bullish sentiments. In a report released…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such... NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on…
Acadia Pharmaceuticals (ACAD) and Zydus Move to Dismiss Patent Lawsuits Ahead of Nuplazid Trial
On October 05, 2026, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) and generic drug manufacturer Zydus jointly requested dismissal of all lawsuits and counterclaims related to their patent dispute over Nuplazid, just weeks before a scheduled…
Acadia Pharmaceuticals Stock Extends A 7-Day Losing Streak To A 25% Loss
Acadia Pharmaceuticals (ACAD) stock has fallen for 7 consecutive trading days, losing 24.7% over that stretch. That erased about $1.1 billion from the company’s market value, which now stands at about $3.4 billion. The stock closed at…
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
ACAD Quick QuoteACAD ALDX Quick QuoteALDX ACIU Quick QuoteACIU PGEN Quick QuotePGEN Year to date, ACAD shares have lost 23.1% against the industry’s 7.3% growth. Acadia reported Daybue net product sales of about $226 million in the first…
Acadia Pharmaceuticals Inc. Announces Allowance of U.S. Patent Application Covering Weight-Banded Dosing of Trofinetide
Acadia Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled ?Methods and Compositions... announced that the United States…
From articles in the 4Search news index.
In the news
Mentioned with
Most coverage from
-
markets.businessinsider.com2
-
zacks.com2
-
accessnewswire.com1
-
biospace.com1
-
gurufocus.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.